Publications

Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab

W Park, G Lopes, D Kwon, V Florou, YK Chae, J Warsch, A Ishkanian, ...

iSEND is an algorithmic model specific for advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors

W Park, V Florou, S Algaze, D Saravia, D Kwon, G Lopes

ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors

W Park, D Kwon, A Desai, V Florou, D Saravia, J Warsch, YK Chae, ...

Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer

Tiesi G, Park W, Gunder M, Rubio G, Berger M, Ardalan B, Livingstone A, Franceschi D

Neutrophil-rich inflammation and PD1/PD-L1 inhibitor resistance in advanced non-small cell lung cancer patients

W Park, S Algaze, V Florou, D Saravia, D Kwon, G Lopes

P1. 07-024 ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors

W Park, D Kwon, A Desai, V Florou, D Saravia, J Warsch, YK Chae, ...

P1. 07-025 correlating ISEND and tumor mutation burden (TMB) with clinical outcomes of advanced non-small cell lung cancer (ANSCLC) patients on nivolumab

W Park, G Lopes, D Kwon, V Florou, YK Chae, J Warsch, A Ishkanian, ...

P2. 07-037 Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab

W Park, D Kwon, D Saravia, A Desai, J Warsch, F Vargas, M El Dinali, ...

P3. 02b-092 Central Nervous System (CNS) Responses to Osimertinib in Brain Metastases from Lung Cancer (NSCLC) with T790M: Effectiveness of the 80 Mg Dose: Topic: EGFR Clinical

W Park, R Mudad

P3. 02c-081 Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: Topic: IT Biomarkers

D Saravia, B Laderian, W Park, A Desai, F Vargas, R Elias, S Warsch, ...

The evolving landscape of oncolytic virotherapy (OV) clinical trials (CT): Meta-analysis.

W Park, S Algaze, S Abi Aad, D Kwon, R Elias, N Acquavella, JR Merchan, ...

Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer

Nagaraju GP, Long TE, Park W, Landry JC, Taliaferro-Smith LT, Farris AB, …

Outcomes of biliary stents in advanced pancreatic cancer in the era of improved systemic therapy.

W Park, PK Mankal, EM O'Reilly

Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3

Ganji PN, Park W, Wen J, Mahaseth H, Landry J, Farris AB, Willingham F, …

Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment

Kang D, Park W, Lee S, Kim JH, Song JJ

Heat shock protein 90 functional inhibition regulates epithelial to mesenchymal transformation, invasion and migration via NF-kB and HIF-1α signaling in colorectal cancer.

P Ganji, TE Long, PM Mummareddi, W Park, FF Willingham, JC Landry, ...

New perspectives of curcumin in cancer prevention

Park W, Amin ARMR, Chen ZG, Shin DM

A comparative analysis of locoregional therapy (hyperthermic intraperitoneal chemotherapy [HIPEC]) and systemic chemotherapy (CT) following cytoreductive surgery in patients …

TS Bekaii-Saab, LK Martin, GD Vallabhaneni, W Park, CA Staley, ...

A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment

Zhang H, Yun S, Batuwangala TD, Steward M, Holmes SD, Pan L, Tighiouart M, Shin HJ, et al.

A Loss of Function Genetic Screen Identifies Determinants of Sensitivity to PARP Inhibitor ABT-888 in Pancreatic Cancer

W Park, BG Pantazides, BF El-Rayes, JW Shelton, DS Yu, JC Landry

A synthetic lethal screen identifies genetic determinants for gemcitabine sensitivity in pancreatic cancer

JC Landry, BG Pantazides, W Park, JW Shelton, SK Maithel, B El-Rayes, ...

Autophagic cell death induced by curcumin is mediated by p38/Beclin 1 to crosstalk with apoptotic cell death in DU145 cells

D Kang, W Park, JH Kim, JJ Song

Clinicopathologic feature and outcome of appendiceal goblet cell carcinoid and neuroendocrine tumor.

W Park, GD Vallabhaneni, LK Martin, V Adsay, CA Staley, SK Maithel, ...

Functional inhibition of HSP90 potentiates the effects of ionizing radiation in colorectal cancer

GP Nagaraju, J Wen, BF El-Rayes, JC Landry, W Park, R Diaz

Ganetespib, an HSP90 Inhibitor, Sensitizes Colorectal Cancers to the Effects of Ionizing Radiation

R Diaz, GP Nagaraju, W Park, BF El-Rayes, JC Landry

Abstract C42: Survival signals differentially turn on during TRAIL or curcumin/TRAIL treatment

S Oh, JH Kim, JJ Song, J Kim, HR Yoon, S Kang, W Park, K Hong, SY Kim, ...